Vor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Vor Bio (Nasdaq: VOR) will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The fireside chat will take place on February 14, 2024, at 10:00 am ET, and will be available for live webcast and archived replay on the company's website. This event presents an opportunity for investors to engage with Vor Bio and gain insights into its clinical-stage cell and genome engineering endeavors.
02/07/2024 - 08:00 AM
CAMBRIDGE, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Oppenheimer 34th Annual Healthcare Life Sciences Conference
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com .
About Vor Bio www.vorbio.com .
Contact: sspencer@vorbio.com
When and where will the Oppenheimer 34th Annual Healthcare Life Sciences Conference Fireside Chat take place?
The Oppenheimer 34th Annual Healthcare Life Sciences Conference Fireside Chat will take place on Wednesday, February 14, 2024, at 10:00 am ET. The location of the event is virtual.
Where can I access the live webcast and archived replay of the fireside chat?
The live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
What is Vor Bio's ticker symbol?
Vor Bio's ticker symbol is VOR.
Vor Biopharma Inc
NASDAQ:VOR
VOR Rankings
#4827 Ranked by Stock Gains
VOR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
About VOR
vor biopharma is pioneering engineered hematopoietic stem cells (ehscs) to dramatically change the treatment paradigm for hematological cancers. vor’s ehscs are designed to generate healthy, fully functional cells with specific advantageous modifications, for example to protect the blood and bone marrow from the toxic effects of antigen-targeted therapies, protecting healthy cells from depletion but leaving tumor cells vulnerable. vor’s platform could potentially be used to change the treatment paradigm of both hematopoietic stem cell transplants and antigen-targeted therapies such as antibody drug conjugates, bispecific antibodies and car-t cell treatments. a proof-of-concept study for vor’s lead program has been published in proceedings of the national academy of sciences. vor is based in cambridge, mass. and has a broad intellectual property base including in-licenses from columbia university, where foundational work was conducted by inventor and vor scientific board chair siddhar
